JulioCChavezMD

Hematologic Oncology

Physician

Overview of Dr. Chavez

Dr. Julio Chavez is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and James A. Haley Veterans' Hospital-Tampa. He received his medical degree from Cayetano Heredia University and has been in practice 17 years. He is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 50 doctors at James A. Haley Veterans' Hospital-Tampa who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(415) 683-1335

Education & Training

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2011 - 2013
University at BuffaloResidency, Internal Medicine, 2008 - 2011
Cayetano Heredia UniversityClass of 2000

Certifications & Licensure

FL State Medical License 2013 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL Start of enrollment: 2012 Mar 30
Active, not recruiting
Phase 2
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia Start of enrollment: 2019 May 31
Terminated
Phase 2
TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2019 Nov 12
Terminated
Phase 2
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma Start of enrollment: 2020 Aug 21
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

3393 citations
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos
The New England Journal of Medicine. 2017-12-10
12 citations
Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
Bhagirathbhai Dholaria, Ernesto Ayala, Lubomir Sokol, Taiga Nishihori, Julio C. Chavez
Leukemia Research. 2018-04-01
448 citations
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chavez
Molecular Therapy. 2017-01-04

Journal Articles

Axicabtagene Ciloleucel (KTE-C19), an Anti-CD19 CAR T Therapy for the Treatment of relapsed/refractory Aggressive B-cell Non-Hodgkin’s Lymphoma
Julio C Chavez, Vania H Phuoc, Therapeutics and Clinical Risk Management

Abstracts/Posters

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
Julio C. Chavez, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Julio C. Chavez, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in C...
Julio C. Chavez, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of Rituximab in the Clinical Outcomes of Hairy Cell Leukemia: A Retrospective Single-Institution Analysis
Julio C. Chavez, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience
Julio C. Chavez, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/9/2019
Join now to see all

Lectures

Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ibrutinib for the Treatment of Bing-Neel Syndrome
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Avadomide (CC-), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Long-Term Data for Kite’s Yescarta® CAR T-cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients with High-Risk Large B-cell LymphomaDecember 13th, 2023
$Mosunetuzumab plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed or Refractory Aggressive Large B Cell Lymphoma$
Mosunetuzumab plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed or Refractory Aggressive Large B Cell LymphomaDecember 23rd, 2023